Adenovirus 5 E1a-mediated gene therapy for human ovarian cancer cells in vitro and in vivo.
The aim of this study was to investigate therapeutic efficacy of adenovirus-mediated E1a gene therapy for ovarian cancer in vitro and in vivo. Recombinant replication-deficient adenoviral vectors were prepared by superinfection of 293 cells, and then purified. The efficacy of the adenovirus vector system to infect ovarian cells was tested using different multiplicity of infection (MOI) and different times (1-4) of Ad.RSVlacZ. SKOV-3 cells (10(3) per well) were infected once with 2 x 10(4) adenovirus. The cells were harvested and counted on different days for 7 days to generate the in vitro growth curve. Tumor-bearing mice were injected intraperitoneally with ovarian cancer cells and treated by intraperitoneal injection of 100 microl (2.5 x 10(8) PFU) viral solution containing either replication-deficient Ad.E1a(+); control virus Ad.E1a(-) which is the same adenovirus as Ad.E1a(+) except for E1a deletion, or just phosphate buffered solution. The transduction efficacy increased with higher MOI and reached a plateau at the 20:1 ratio. When Ad.E1a(+) was used to transduce the HER-2/neu overexpressing human ovarian cancer cell line SKOV-3, tumor cell growth in vitro was greatly inhibited by E1a transduction. Also, Ad.E1a+ greatly inhibited tumor growth of SKOV-3-bearing mice. Immunohistochemistry analysis indicated that Ad.E1a protein was expressed in tumor tissue and expression of HER-2/neu p185 protein was suppressed. Very strong beta-gal staining was detected in tumors, and beta-gal activity in small intestine, lung, heart, stomach, liver, and kidney was detected. No beta-gal activity was detected in the tumor and other organs in control mice injected with Ad.E1a(-) or PBS. Adenovirus-type 5 E1a gene can efficaciously inhibit HER-2/neu-overexpressing ovarian cancer, and this promising procedure could greatly benefit ovarian cancer patients with high expression of HER-2/neu.
Zang
R Y
RY
Department of Gynecological Oncology, Cancer Hospital and Cancer Institute, Shanghai, China. ryzang@hotmail.com
Shi
D R
DR
Lu
H J
HJ
Cai
S M
SM
Lu
D R
DR
Zhang
Y J
YJ
Qin
H L
HL
D000256:Adenoviridae / Q000472:pathogenicity; D017500:Adenovirus E1A Proteins / Q000235:genetics*; D000818:Animals; D002277:Carcinoma / Q000235:genetics* / Q000628:therapy*; D015536:Down-Regulation; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000628:therapy*; D010446:Peptide Fragments / Q000096:biosynthesis; D011897:Random Allocation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured
D017500:Adenovirus E1A Proteins; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases; C091577:HER2-neu-derived peptide (654-662)